Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4Withdrawn 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 4Breast 4Tumor-Agnostic 3Other hematologic neoplasm 3Sarcoma 2Plasma cell 1Other solid neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × STA 9090 × Breast × Clear all
NCT01560416 2026-03-03

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
50 enrolled 14 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02060253 2018-06-14

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
9 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01273896 2015-11-20

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
22 enrolled 6 charts
Breast

Breast Neoplasms

NCT01677455 2015-11-05

Enchant

Synta Pharmaceuticals Corp.

Phase 2 Completed
51 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡